

**From:** no-reply@copyright.com  
**Sent:** dinsdag 28 juli 2020 15:47  
**To:** Jan A Staessen  
**Subject:** Thank you for your order with RightsLink / Elsevier



## Thank you for your order!

Dear Jan Staessen,

Thank you for placing your order through Copyright Clearance Center's RightsLink® service.

### Order Summary

Licensee: Jan Staessen  
Order Date: Jul 28, 2020  
Order Number: 4877660221880  
Publication: Research in Social and Administrative Pharmacy  
Title: The uses and expenses of antihypertensive medications among hypertensive adults  
Type of Use: reuse in a journal/magazine  
Order Total: 0.00 EUR

View or print complete [details](#) of your order and the publisher's terms and conditions.

Sincerely,

Copyright Clearance Center

Tel: +1-855-239-3415 / +1-978-646-2777  
[customercare@copyright.com](mailto:customercare@copyright.com)  
<https://myaccount.copyright.com>



This message (including attachments) is confidential, unless marked otherwise. It is intended for the addressee(s) only. If you are not an intended recipient, please delete it without further distribution and reply to the sender that you have received the message in error.

ELSEVIER LICENSE  
TERMS AND CONDITIONS

Oct 22, 2020

---

---

This Agreement between Jan Staessen ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

License Number	4877660221880
License date	Jul 28, 2020
Licensed Content Publisher	Elsevier
Licensed Content Publication	Research in Social and Administrative Pharmacy
Licensed Content Title	The uses and expenses of antihypertensive medications among hypertensive adults
Licensed Content Author	Chanhyun Park,Guijing Wang,Boon Peng Ng,Jing Fang,Jeffrey M. Durthaler,Carma Ayala
Licensed Content Date	Feb 1, 2020
Licensed Content Volume	16
Licensed Content Issue	2
Licensed Content Pages	7
Start Page	183
End Page	189
Type of Use	reuse in a journal/magazine

Requestor type	academic/educational institute
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	1
Format	both print and electronic
Are you the author of this Elsevier article?	No
Will you be translating?	No
Title of new article	Starting Antihypertensive Treatment with Combination Therapy - Con Side of the Argument
Lead author	Zhen-Yu Zhang
Title of targeted journal	Hypertension
Publisher	Wolters Kluwer Health, LWW
Publisher imprint	Lippincott Williams & Wilkins
Expected publication date	Sep 2020
Portions	Fig. 1
Requestor Location	Jan Staessen Kapucijnenvoer 35 block D, Box 7001 Leuven, B-3000 Belgium Attn: Jan Staessen
Publisher Tax ID	GB 494 6272 12
Total	0.00 EUR

Terms and Conditions

## INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

## GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at [permissions@elsevier.com](mailto:permissions@elsevier.com)). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. **Warranties:** Publisher makes no representations or warranties with respect to the licensed material.

10. **Indemnity:** You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. **No Transfer of License:** This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.

12. **No Amendment Except in Writing:** This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).

13. **Objection to Contrary Terms:** Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

14. **Revocation:** Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

### LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world **English** rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.

16. **Posting licensed content on any Website:** The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com> . All content posted to the web site must maintain the copyright information line on the bottom of each image.

**Posting licensed content on Electronic reserve:** In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to

bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

17. **For journal authors:** the following clauses are applicable in addition to the above:

### **Preprints:**

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

**Accepted Author Manuscripts:** An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
  - via their non-commercial person homepage or blog
  - by updating a preprint in arXiv or RePEc with the accepted manuscript
  - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
  - directly by providing copies to their students or to research collaborators for their personal use
  - for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period
  - via non-commercial hosting platforms such as their institutional repository
  - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

**Published journal article (JPA):** A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

**Subscription Articles:** If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version.

Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

**Gold Open Access Articles:** May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

18. **For book authors** the following clauses are applicable in addition to the above: Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

19. **Thesis/Dissertation:** If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

### **Elsevier Open Access Terms and Conditions**

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

#### **Terms & Conditions applicable to all Open Access articles published with Elsevier:**

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

#### **Additional Terms & Conditions applicable to each Creative Commons user license:**

**CC BY:** The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

**CC BY NC SA:** The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

**CC BY NC ND:** The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>. Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

## 20. Other Conditions:

v1.9

Questions? [customercare@copyright.com](mailto:customercare@copyright.com) or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.

---

---



Vera De Leebeek

---

**From:** no-reply@copyright.com  
**Sent:** dinsdag 28 juli 2020 15:19  
**To:** Jan A Staessen  
**Subject:** Thank you for your order with RightsLink / BMJ Publishing Group Ltd.



## Thank you for your order!

Dear Jan Staessen,

Thank you for placing your order through Copyright Clearance Center's RightsLink® service.

### Order Summary

Licensee: Jan Staessen  
Order Date: Jul 28, 2020  
Order Number: 4877650053916  
Publication: Heart  
Title: JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice  
Type of Use: Journal/Magazine  
Order Total: 0.00 EUR

View or print complete [details](#) of your order and the publisher's terms and conditions.

Sincerely,

Copyright Clearance Center

Tel: +1-855-239-3415 / +1-978-646-2777  
[customercare@copyright.com](mailto:customercare@copyright.com)  
<https://myaccount.copyright.com>



This message (including attachments) is confidential, unless marked otherwise. It is intended for the addressee(s) only. If you are not an intended recipient, please delete it without further distribution and reply to the sender that you have received the message in error.

BMJ PUBLISHING GROUP LTD. LICENSE  
TERMS AND CONDITIONS

Oct 22, 2020

---

This Agreement between Jan Staessen ("You") and BMJ Publishing Group Ltd. ("BMJ Publishing Group Ltd.") consists of your license details and the terms and conditions provided by BMJ Publishing Group Ltd. and Copyright Clearance Center.

License Number	4877650053916
License date	Jul 28, 2020
Licensed Content Publisher	BMJ Publishing Group Ltd.
Licensed Content Publication	Heart
Licensed Content Title	JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Licensed Content Author	Prepared by: British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association
Licensed Content Date	Dec 1, 2005
Licensed Content Volume	91
Licensed Content Issue	suppl 5
Type of Use	Journal/Magazine
Requestor type	Academic Institution
Format	Print and electronic

Portion	Figure/table/extract
Number of figure/table/extracts	1
Description of figure/table/extracts	Figure 4 Recommendation for combining blood pressure drugs/ABCD rule
Will you be translating?	No
Circulation/distribution	1000
Title of new article	Starting Antihypertensive Treatment with Combination Therapy - Con Side of the Argument
Lead author	Zhen-Yu Zhang
Title of targeted journal	Hypertension
Publisher	Wolters Kluwers
Publisher imprint	Lippincott Williams & Wilkins
Expected publication date	Sep 2020
Portions	Figure 4 Recommendation for combining blood pressure drugs/ABCD rule
Requestor Location	Jan Staessen Kapucijnenvoer 35 block D, Box 7001 Leuven, B-3000 Belgium Attn: Jan Staessen
Publisher Tax ID	GB674738491
Total	0.00 EUR

### BMJ Group Terms and Conditions for Permissions

When you submit your order you are subject to the terms and conditions set out below. You will also have agreed to the Copyright Clearance Center's ("CCC") terms and conditions regarding billing and payment <https://s100.copyright.com/App/PaymentTermsAndConditions.jsp>. CCC are acting as the BMJ Publishing Group Limited's ("BMJ Group's") agent.

Subject to the terms set out herein, the BMJ Group hereby grants to you (the Licensee) a non-exclusive, non-transferable licence to re-use material as detailed in your request for this/those purpose(s) only and in accordance with the following conditions:

1) **Scope of Licence:** Use of the Licensed Material(s) is restricted to the ways specified by you during the order process and any additional use(s) outside of those specified in that request, require a further grant of permission.

2) **Acknowledgement:** In all cases, due acknowledgement to the original publication with permission from the BMJ Group should be stated adjacent to the reproduced Licensed Material. The format of such acknowledgement should read as follows:

"Reproduced from [publication title, author(s), volume number, page numbers, copyright notice year] with permission from BMJ Publishing Group Ltd."

3) **Third Party Material:** BMJ Group acknowledges to the best of its knowledge, it has the rights to licence your reuse of the Licensed Material, subject always to the caveat that images/diagrams, tables and other illustrative material included within, which have a separate copyright notice, are presumed as excluded from the licence. Therefore, you should ensure that the Licensed Material you are requesting is original to BMJ Group and does not carry the copyright of another entity (as credited in the published version). If the credit line on any part of the material you have requested in any way indicates that it was reprinted or adapted by BMJ Group with permission from another source, then you should seek permission from that source directly to re-use the Licensed Material, as this is outside of the licence granted herein.

4) **Altering/Modifying Material:** The text of any material for which a licence is granted may not be altered in any way without the prior express permission of the BMJ Group. Subject to Clause 3 above however, single figure adaptations do not require BMJ Group's approval; however, the adaptation should be credited as follows:

"Adapted by permission from BMJ Publishing Group Limited. [publication title, author, volume number, page numbers, copyright notice year]"

5) **Reservation of Rights:** The BMJ Group reserves all rights not specifically granted in the combination of (i) the licence details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment Terms and Conditions.

6) **Timing of Use:** First use of the Licensed Material must take place within 12 months of the grant of permission.

7) **Creation of Contract and Termination:** Once you have submitted an order via Rightslink and this is received by CCC, and subject to you completing accurate details of your proposed use, this is when a binding contract is in effect and our acceptance occurs. As you are ordering rights from a periodical, to the fullest extent permitted by law, you will have no right to cancel the contract from this point other than for BMJ Group's material breach or fraudulent misrepresentation or as otherwise permitted under a statutory right. Payment must be made in accordance with CCC's Billing and Payment Terms and conditions. In the event that you breach any material condition of these terms and condition or any of CCC's Billing and Payment Terms and Conditions, the license is automatically terminated upon written notice from the BMJ Group or CCC or as otherwise provided for in CCC's Billing and Payment Terms and Conditions, where these apply. Continued use of materials where a licence has been terminated, as well as any use of the Licensed Materials beyond the scope of an unrevoked licence, may constitute intellectual property rights infringement and BMJ Group reserves the right to take any and all action to protect its intellectual property rights in the Licensed Materials.

8. **Warranties:** BMJ Group makes no express or implied representations or warranties with respect to the Licensed Material and to the fullest extent permitted by law this is provided on an "as is" basis. For the avoidance of doubt BMJ Group does not warrant that the Licensed Material is accurate or fit for any particular purpose.

9. **Limitation of Liability:** To the fullest extent permitted by law, the BMJ Group disclaims all liability for any indirect, consequential or incidental damages (including without limitation, damages for loss of profits, information or interruption) arising out of the use or inability to use the Licensed Material or the inability to obtain additional rights to use the Licensed Material. To the fullest extent permitted by law, the maximum aggregate liability of the BMJ Group for any claims, costs, proceedings and demands for direct losses caused by BMJ Group's breaches of its obligations herein shall be limited to twice the amount paid by you to CCC for the licence granted herein.

10. **Indemnity:** You hereby indemnify and hold harmless the BMJ Group and their respective officers, directors, employees and agents, from and against any and all claims, costs, proceeding or demands arising out of your unauthorised use of the Licensed Material.

11. **No Transfer of License:** This licence is personal to you, and may not be assigned or transferred by you without prior written consent from the BMJ Group or its authorised agent(s). BMJ Group may assign or transfer any of its rights and obligations under this Agreement, upon written notice to you.

12. **No Amendment Except in Writing:** This licence may not be amended except in a writing signed by both parties (or, in the case of BMJ Group, by CCC on the BMJ Group's behalf).

13. **Objection to Contrary terms:** BMJ Group hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment Terms and Conditions. These terms and conditions, together with CCC's Billing and Payment Terms and Conditions (which to the extent they are consistent are incorporated herein), comprise the entire agreement between you and BMJ Group (and CCC) and the Licensee concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment Terms and Conditions, these terms and conditions shall control.

14. **Revocation:** BMJ Group or CCC may, within 30 days of issuance of this licence, deny the permissions described in this licence at their sole discretion, for any reason or no reason, with a full refund payable to you should you have not been able to exercise your rights in full. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice from BMJ Group or CCC will not, to the fullest extent permitted by law alter or invalidate the denial. For the fullest extent permitted by law in no event will BMJ Group or CCC be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to BMJ Group and/or CCC for denied permissions.

#### 15. **Restrictions to the licence:**

15.1 **Promotion:** BMJ Group will not give permission to reproduce in full or in part any Licensed Material for use in the promotion of the following:

a) non-medical products that are harmful or potentially harmful to health: alcohol, baby milks and/or, sunbeds

b) medical products that do not have a product license granted by the Medicines and Healthcare products Regulatory Agency (MHRA) or its international equivalents. Marketing of the product may start only after data sheets have been released to members of the medical profession and must conform to the marketing authorization contained in the product license.

16. **Translation:** This permission is granted for non-exclusive world English language rights only unless explicitly stated in your licence. If translation rights are granted, a professional translator should be employed and the content should be reproduced word for word preserving the integrity of the content.

17. **General:** Neither party shall be liable for failure, default or delay in performing its obligations under this Licence, caused by a Force Majeure event which shall include any act of God, war, or threatened war, act or threatened act of terrorism, riot, strike, lockout, individual action, fire, flood, drought, tempest or other event beyond the reasonable control of either party.

17.1 In the event that any provision of this Agreement is held to be invalid, the remainder of the provisions shall continue in full force and effect.

17.2 There shall be no right whatsoever for any third party to enforce the terms and conditions of this Agreement. The Parties hereby expressly wish to exclude the operation of the Contracts (Rights of Third Parties) Act 1999 and any other legislation which has this effect and is binding on this agreement.

17.3 To the fullest extent permitted by law, this Licence will be governed by the laws of England and shall be governed and construed in accordance with the laws of England. Any action arising out of or relating to this agreement shall be brought in court situated in England save where it is necessary for BMJ Group for enforcement to bring proceedings to bring an action in an alternative jurisdiction.

**Questions? [customercare@copyright.com](mailto:customercare@copyright.com) or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.**

---

---

PMC full text: [J Am Heart Assoc. 2017 Nov; 6\(11\): e006986.](#)

[<< Prev](#) [Figure 3](#) [Next >>](#)

Published online 2017 Nov 18. doi: [10.1161/JAHA.117.006986](#)


[Copyright/License](#)

[Request permission to reuse](#)

Copyright © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

**Figure 3**



[Open in a separate window](#)

Home systolic BP. A, Means at each visit in each of the monotherapy and combination therapy arms. Unadjusted mean home systolic BP (95% confidence interval) at each visit. B, Responder rates at the end of each phase. C, Means measured on maximum dose of combination therapy and each monotherapy by tertiles of renin mass measured before treatment. Unadjusted mean home systolic BP by renin tertile. BP indicates blood pressure; HCTZ, hydrochlorothiazide.